Search

Displaying results 3601 - 3610 of 7897 in total
  1. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    [L15302] Its relative ubiquity across different stages of B-cell development, including pre-B and mature B-lymphocytes,[L15292] as well as its presence in several B-cell malignancies (e.g. chronic lymphocytic … Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies.

    Categories: Lymphoma, B-Cell
  2. Drug

    AT9283

    go.drugbank.com/drugs/DB05169
    Investigational

    AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer.

  3. Drug

    Miltefosine

    go.drugbank.com/drugs/DB09031
    ApprovedInvestigational

    Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. … The CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis.

  4. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  5. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. … Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).

  6. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits

  7. Drug

    CT103A

    go.drugbank.com/drugs/DB18180
    Investigational

    CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.

  8. Drug

    CT120

    go.drugbank.com/drugs/DB18181
    Investigational

    CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.

  9. Drug

    CAM-101

    go.drugbank.com/drugs/DB18414
    Investigational

    CAM-101 is an allogeneic human platelet lysate product depleted of fibrinogen.

  10. Drug

    Salanersen

    go.drugbank.com/drugs/DB18418
    Investigational

    BIIB115 is an investigational antisense oligonucleotide in development for spinal muscular atrophy.